{"Title": "Concerns about how to use established minimal residual disease monitoring in the treatment of NPM1-mutant acute myeloid leukaemia (AML) following reduced intensity chemotherapy protocols for AML given as a result of the COVID-19 pandemic", "Year": 2020, "Source": "Br. J. Haematol.", "Volume": "190", "Issue": 4, "Art.No": null, "PageStart": null, "PageEnd": null, "CitedBy": 1, "DOI": "10.1111/bjh.16985", "Link": "https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85088452761&origin=inward", "Abstract": null, "AuthorKeywords": ["acute leukaemia", "AML", "molecular genetics", "molecular haematology", "MRD"], "IndexKeywords": ["Adult", "Antineoplastic Combined Chemotherapy Protocols", "COVID-19", "Cytarabine", "Daunorubicin", "Gemtuzumab", "Humans", "Leukemia, Myeloid, Acute", "Male", "Mutation", "Neoplasm, Residual", "Nuclear Proteins", "SARS-CoV-2"], "DocumentType": "Journal", "PublicationStage": null, "OpenAccess": 1, "EID": "2-s2.0-85088452761", "SubjectAreas": [["Hematology", "MEDI", "2720"]], "AuthorData": {"57193727619": {"Name": "Farah N.", "AuthorID": "57193727619", "AffiliationID": "60109234, 60022148", "AffiliationName": "UCL Cancer Institute, UCL"}, "57218245851": {"Name": "Burt R.", "AuthorID": "57218245851", "AffiliationID": "60024544", "AffiliationName": "Department of Haematology, University College Hospitals NHS Foundation Trust"}, "57218248546": {"Name": "Ibrahim A.R.", "AuthorID": "57218248546", "AffiliationID": "60024544", "AffiliationName": "Department of Haematology, University College Hospitals NHS Foundation Trust"}, "57218168819": {"Name": "Baker R.", "AuthorID": "57218168819", "AffiliationID": "113068888", "AffiliationName": "Molecular Pathology, Health Services Laboratories, The Halo Building"}, "6701389817": {"Name": "Kottaridis P.D.", "AuthorID": "6701389817", "AffiliationID": "60024544", "AffiliationName": "Department of Haematology, University College Hospitals NHS Foundation Trust"}}}